Shots: The P-III PROVENT & TACKLE trial evaluates AZD7442 (IM) vs PBO in a ratio (2:1) & (1:1) in 5197 & 903 patients with COVID-19 In the PROVENT trial, AZD7442 […]readmore
Tags : COVID-19
Shots: The EC has granted marketing authorisation for Celltrion’s regdanvimab in adults with COVID-19 who do not require supplemental oxygen & are at high risk of progressing to severe COVID-19 […]readmore
Shots: The P-III COMET-TAIL trial evaluates the efficacy, safety & tolerability of sotrovimab (250/500mg, given as IM compared to IV) in 983 high-risk patients aged ≥12yrs. with COVID-19 for 7 […]readmore
Shots: The EMA’s CHMP has issued a positive opinion recommending the marketing authorization for regdanvimab (CT-P59) in adults with COVID-19 who do not require supplemental oxygen & are at increased […]readmore
Clinical Trials
COVID-19
Regeneron Reports Results of REGEN-COV (casirivimab and imdevimab) in P-III
Shots: The P-III trial evaluates REGEN-COV (1200mg, SC) vs PBO in a ratio (1:1) in patients who lived in the same household with COVID-19 patients diagnosed within the prior 4 […]readmore
Shots: The P-II/III EPIC-HR evaluates Paxlovid vs PBO in non-hospitalized adult patients with COVID-19 who are at high risk of progressing to severe illness In an interim analysis, the therapy […]readmore
Shots: The US FDA’s VRBPAC voted 17 to 0 with 1 abstention in favor of recommending the EUA for COVID-19 vaccine in children aged 5 to <12yrs. with COVID-19 The […]readmore
Shots: The P-II/III KidCOVE study evaluated the safety, tolerability, reactogenicity & effectivity of mRNA-1273 in 4753 children aged 6-12yrs. with COVID-19, administered as 28 days apart The study met its […]readmore
Shots: The submission is based on the P-III MOVe-OUT trial that evaluates molnupiravir (800mg, bid) in non-hospitalized adult patients with COVID-19 At the interim analysis, the therapy showed a ~50% […]readmore
Shots: The P-III trial evaluates a booster dose of COVID-19 vaccine (30µg) in a ratio (1:1) in 10000+ individuals aged ≥16yrs. with COVID-19 who previously received the primary two-dose series […]readmore